HARVARD BIOSCIENCE INC — Director's Dealing 2016

Nov 3, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2016-11-03

Reporting Person: Duchemin Jeffrey (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-03	Common Stock	P	15000	$2.42	Acquired	462623	Direct

Footnotes

F1: This transaction was executed in several trades between $2.35 and $2.50. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Includes (a) a deferred stock award of 291,667 restricted stock units which shall vest in four equal installments on January 1, 2017, 2018, 2019 and 2020; (b) a deferred stock award of 51,675 restricted stock units which shall vest in three equal installments on January 1, 2017, 2018 and 2019; (c) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (c) 47,533 shares of common stock held by the Reporting Person.